The higher amounts of tumor-specific antigens induced by MMR gene mutations, which in turn increases the anti-tumor immune response, may account for the greater therapeutic effect of ICIs in MMR-deficient tumors compared to non-MMR-deficient cancers [147]. This evidence concerns the gene MRC1 and neoplasm.